50 results on '"Nieuwenhuizen, Laurens"'
Search Results
2. Targeted exome analysis in patients with rare bleeding disorders: data from the Rare Bleeding Disorders in the Netherlands study
3. Predictive performance of pharmacokinetic-guided prophylactic dosing of factor concentrates in hemophilia A and B
4. High prevalence of heavy menstrual bleeding in women with rare bleeding disorders in the Netherlands: retrospective data from the RBiN study
5. Little discrepancy between one-stage and chromogenic factor VIII (FVIII)/IX assays in a large international cohort of persons with nonsevere hemophilia A and B
6. High prevalence of postpartum hemorrhage in women with rare bleeding disorders in the Netherlands: retrospective data from the RBiN study
7. SYMPHONY consortium: Orchestrating personalized treatment for patients with bleeding disorders
8. Treatment of patients with rare bleeding disorders in the Netherlands: Real‐life data from the RBiN study
9. Fibrinolytic assays in bleeding of unknown cause: Improvement in diagnostic yield
10. Von Willebrand disease type 2M: Correlation between genotype and phenotype
11. Fixed Versus Variable Dosing of Prothrombin Complex Concentrate for Bleeding Complications of Vitamin K Antagonists—The PROPER3 Randomized Clinical Trial
12. Health and treatment outcomes of patients with hemophilia in the Netherlands, 1972–2019
13. Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial
14. Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001–2018
15. Heavy menstrual bleeding on direct factor Xa inhibitors: Rationale and design of the MEDEA study
16. Bleeding severity in patients with rare bleeding disorders: real-life data from the RBiN study
17. Peri‐operative desmopressin combined with pharmacokinetic‐guided factor VIII concentrate in non‐severe haemophilia A patients.
18. Transition readiness among adolescents and young adults with haemophilia in the Netherlands: Nationwide questionnaire study
19. Little discrepancy between one-stage and chromogenic factor VIII (FVIII)/IX assays in a large international cohort of persons with nonsevere hemophilia A and B
20. Little discrepancy between one-stage and chromogenic FVIII/IX assays in a large international cohort of persons with non-severe hemophilia A and B
21. Harnessing Cell-Free DNA Biological Features for Early Treatment Response Prediction in High Grade B-Cell Lymphoma
22. First-Line Treatment of Waldenström’s Macroglobulinaemia: Considerations Based on the Dutch National Guideline
23. The value of leukapheresis for treatment of priapism as presenting feature of chronic myeloid leukemia—Case report and review of literature
24. Desmopressin for bleeding in non‐severe hemophilia A: Suboptimal use in a real‐world setting
25. Hemarthrosis in hemophilic mice results in alterations in M1-M2 monocyte/macrophage polarization
26. The Use of Galactomannan Antigen Assays for the Diagnosis of Invasive Pulmonary Aspergillosis in the Hematological Patient: A Systematic Review and Meta-Analysis.
27. Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial
28. Impact of extreme weight loss on factor VIII concentrate pharmacokinetics in haemophilia
29. A single intra-articular injection with IL-4 plus IL-10 ameliorates blood-induced cartilage degeneration in haemophilic mice
30. SYMPHONYconsortium: Orchestrating personalized treatment for patients with bleeding disorders
31. A review of pulmonary coagulopathy in acute lung injury, acute respiratory distress syndrome and pneumonia
32. Central nervous system myelomatosis: review of the literature
33. Dosing of factor VIII concentrate by ideal body weight is more accurate in overweight and obese haemophilia A patients.
34. Broad Bands Observed in Serum Electrophoresis Should Not Be Taken Lightly
35. Desmopressin treatment combined with clotting factor VIII concentrates in patients with non-severe haemophilia A: protocol for a multicentre single-armed trial, the DAVID study
36. von Willebrand Factor and Factor VIII Clearance in Perioperative Hemophilia A Patients.
37. Sports participation and physical activity in patients with von Willebrand disease.
38. DA-EPOCH-R for High Grade B-Cell Lymphoma Patients with MYC and BCL2 and/or BCL6 Rearrangements: Clinical Results of the Induction Phase of the HOVON-152 Trial
39. Deferasirox limits cartilage damage following haemarthrosis in haemophilic mice
40. Haemarthrosis stimulates the synovial fibrinolytic system in haemophilic mice
41. A single intra-articular injection with IL-4 plus IL-10 ameliorates blood-induced cartilage degeneration in haemophilic mice
42. Raising the arm before cuff inflation increases the loudness of Korotkoff sounds
43. Central nervous system myelomatosis: review of the literature
44. Deferasirox limits cartilage damage following haemarthrosis in haemophilic mice.
45. Haemarthrosis stimulates the synovial fibrinolytic system in haemophilic mice.
46. A single intra-articular injection with IL-4 plus IL-10 ameliorates blood-induced cartilage degeneration in haemophilic mice.
47. [Dog saliva causes rare and life-threatening infection].
48. Dosing of factor VIII concentrate by ideal body weight is more accurate in overweight and obese haemophilia A patients.
49. Heavy menstrual bleeding on direct factor Xa inhibitors: Rationale and design of the MEDEA study.
50. A possible role of 18F-FDG positron-emission tomography scanning in the early detection of rituximab-induced pneumonitis in patients with non-Hodgkin's lymphoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.